Every 10-Q that Elicio Therapeutics, Inc. (ELTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ELTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELTX filings page.
Elicio Therapeutics, Inc. is a clinical-stage biotech focused on AMP-based cancer immunotherapies, led by ELI-002 7P for mKRAS-positive pancreatic and other solid tumors. For the six months ended June 30, 2026, it reported a net loss of $20.0 million, slightly lower than $21.8 million a year earlier, on operating expenses of $21.0 million. Cash and cash equivalents were $23.5 million, with total assets of $31.3 million and a long-term debt balance of about $9.5 million on a $10.0 million senior secured promissory note.
The Phase 2 AMPLIFY-7P trial in adjuvant mKRAS-driven PDAC did not meet its pre-specified primary disease-free survival endpoint in the intent-to-treat population, though management highlights early DFS separation during treatment, favorable safety, and stronger effects in certain subgroups to refine a planned Phase 3 strategy. Management discloses substantial doubt about the company’s ability to continue as a going concern, expecting its cash to fund operations only into the first quarter of 2027. To bolster liquidity, Elicio raised approximately $24.4 million via at-the-market equity programs in the first half of 2026 and a further $13.6 million in a July 2026 registered direct offering, but anticipates needing additional capital to advance trials and sustain operations.
Elicio Therapeutics reported a net loss of $11.8 million for the three months ended March 31 2026, as it continues developing its AMP-based cancer immunotherapies. Operating expenses were $10.6 million, led by $6.8 million in research and development and $3.8 million in general and administrative costs.
Cash and cash equivalents were $14.9 million with total assets of $22.7 million and stockholders’ deficit of $1.4 million as of March 31 2026. Management discloses substantial doubt about the company’s ability to continue as a going concern, estimating its current cash runway extends into the fourth quarter of 2026.
To bolster liquidity, Elicio raised net proceeds of about $8.0 million in the quarter through at-the-market equity programs and carries a $10.0 million Senior Secured Promissory Note bearing interest of up to 12.5%. The company expects continued losses as it advances its Phase 2 ELI-002 7P program and preclinical pipeline.
Elicio Therapeutics (ELTX) reported Q3 2025 results with a net loss of $10.1 million and total operating expenses of $8.0 million, down from $10.3 million a year ago. Year to date, net loss was $31.9 million.
Cash and cash equivalents were $20.6 million as of September 30, 2025. Management disclosed that these resources and expected needs raise substantial doubt about the company’s ability to continue as a going concern. Stockholders’ equity improved to $3.8 million from a $(11.3) million deficit at year-end 2024, reflecting capital actions.
During 2025, Elicio converted a $20.0 million senior secured convertible note (plus $0.3 million interest) into 3,500,573 shares in March, raised $9.2 million net in a January registered direct offering with accompanying warrants, generated $11.4 million net via ATM sales, and issued a $10.0 million senior secured promissory note in June with a warrant. Shares outstanding were 17,489,516 as of November 10, 2025.